CA3079837A1 - Analyte detection method - Google Patents

Analyte detection method Download PDF

Info

Publication number
CA3079837A1
CA3079837A1 CA3079837A CA3079837A CA3079837A1 CA 3079837 A1 CA3079837 A1 CA 3079837A1 CA 3079837 A CA3079837 A CA 3079837A CA 3079837 A CA3079837 A CA 3079837A CA 3079837 A1 CA3079837 A1 CA 3079837A1
Authority
CA
Canada
Prior art keywords
sample
cms
biocompatible solution
blood
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3079837A
Other languages
English (en)
French (fr)
Inventor
Gary PALTZ
Manhong Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA3079837A1 publication Critical patent/CA3079837A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150015—Source of blood
    • A61B5/150022—Source of blood for capillary blood or interstitial fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B10/0051—Devices for taking samples of body liquids for taking saliva or sputum samples
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B10/0058—Devices for taking samples of body liquids for taking sperm samples
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B10/0064—Devices for taking samples of body liquids for taking sweat or sebum samples
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B10/007—Devices for taking samples of body liquids for taking urine samples
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B2010/0067—Tear or lachrymal fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B2010/0077—Cerebrospinal fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2503/00—Evaluating a particular growth phase or type of persons or animals
    • A61B2503/04—Babies, e.g. for SIDS detection
    • A61B2503/045—Newborns, e.g. premature baby monitoring
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0627—Sensor or part of a sensor is integrated
    • B01L2300/0636—Integrated biosensor, microarrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/12—Specific details about materials
    • B01L2300/126—Paper

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ecology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
CA3079837A 2017-11-01 2018-10-31 Analyte detection method Pending CA3079837A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762580277P 2017-11-01 2017-11-01
US62/580,277 2017-11-01
US201862615576P 2018-01-10 2018-01-10
US62/615,576 2018-01-10
PCT/US2018/058440 WO2019089746A1 (en) 2017-11-01 2018-10-31 Analyte detection method

Publications (1)

Publication Number Publication Date
CA3079837A1 true CA3079837A1 (en) 2019-05-09

Family

ID=66332715

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3079837A Pending CA3079837A1 (en) 2017-11-01 2018-10-31 Analyte detection method

Country Status (6)

Country Link
US (1) US20210086176A1 (cg-RX-API-DMAC10.html)
EP (1) EP3704466B1 (cg-RX-API-DMAC10.html)
JP (1) JP7359772B2 (cg-RX-API-DMAC10.html)
CN (1) CN111295577A (cg-RX-API-DMAC10.html)
CA (1) CA3079837A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019089746A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4154268A1 (en) * 2020-05-19 2023-03-29 Sanofi Systems for verification of drug levels using dried blood samples
CN114740127A (zh) * 2022-05-16 2022-07-12 杭州度安医学检验实验室有限公司 一种基于lc-ms/ms检测5种抗肿瘤药物的试剂盒和方法
CN114994198B (zh) * 2022-05-20 2023-02-28 上海市精神卫生中心（上海市心理咨询培训中心） 一种液相色谱质谱联用法同时定量检测78种神经精神类药物的方法
KR102826451B1 (ko) * 2023-09-01 2025-06-27 사회복지법인 삼성생명공익재단 신생아로부터 비침습적으로 분리된 검체를 이용한 신생아의 검체 분석 방법
CN117783507B (zh) * 2024-02-27 2024-06-04 广州科方生物技术股份有限公司 一种通用于(1-3)-β-D葡聚糖及半乳甘露聚糖检测中组分液及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503198B1 (en) * 1997-09-11 2003-01-07 Jack L. Aronowtiz Noninvasive transdermal systems for detecting an analyte obtained from or underneath skin and methods
US20010016317A1 (en) * 1999-09-13 2001-08-23 Dolores M. Berger Method for providing long term stability to cells for diagnostic testing
US6916608B2 (en) * 1999-09-10 2005-07-12 Becton, Dickinson And Company Composition for providing long term stability to cells for diagnostic testing
AU2001247195A1 (en) * 2000-01-31 2001-08-07 Board Of Regents, The University Of Texas System Method and system for collecting and transmitting chemical information
US20030029254A1 (en) * 2001-06-26 2003-02-13 Hvidtfeldt Kristian J. Blood analyzer
US20120003685A1 (en) * 2001-07-19 2012-01-05 Amnon Kritzman Diagnostic composition and article for monitoring intravaginal infections
GB0411387D0 (en) * 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
JP2010515012A (ja) * 2006-10-30 2010-05-06 ジョージ メイソン インテレクチュアル プロパティーズ，インコーポレイテッド オブ フェアファックス，バージニア 組織保存および固定方法
US7914999B2 (en) * 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
GB0716427D0 (en) * 2007-08-23 2007-10-03 Smartsensor Telemed Ltd Glucose tolerance test device
AR072657A1 (es) * 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
EP2517012B1 (en) * 2009-12-23 2019-05-22 Cellestis Limited An assay for measuring cell-mediated immunoresponsiveness
IT1397866B1 (it) * 2009-12-23 2013-02-04 Azienda Ospedaliero Universitaria Meyer Metodo e kit per la determinazione di metaboliti su campioni di sangue depositato su carta bibula (dried blood spot).
CA2766635C (en) * 2011-02-04 2019-08-06 Phytronix Technologies Inc. Sample preparation for mass spectrometry analysis systems
CA2768796A1 (en) * 2011-02-22 2012-08-22 Wellspring Pharmaceutical Corporation Phenoxybenzamine assay
TW201741663A (zh) * 2011-12-29 2017-12-01 陶氏農業科學公司 利用鹼皂化作用來對植物組織樣本總油含量進行比色測定之技術
WO2014150900A1 (en) * 2013-03-15 2014-09-25 Baylor Research Institute Methods and compositions for enhanced analyte detection from blood
JP6773951B2 (ja) * 2014-05-30 2020-10-21 学校法人東京医科大学 唾液試料の調製方法
CN105636937B (zh) * 2015-01-27 2018-07-17 深圳华大生命科学研究院 用于保存生物样品的稳定剂
WO2016134324A1 (en) * 2015-02-20 2016-08-25 Neoteryx, Llc Method and apparatus for acquiring blood for testing
JP2018515796A (ja) * 2015-05-27 2018-06-14 クエスト ダイアグノスティックス インヴェストメンツ エルエルシー マイクロサンプリングデバイスにより抽出された被分析物の質量分析による定量のための方法
EP3139171B1 (en) * 2015-09-02 2020-02-12 Labsystems Diagnostics Oy Novel methods and kits for detecting of urea cycle disorders using mass spectrometry
JP6622050B2 (ja) * 2015-10-07 2019-12-18 キヤノンメディカルシステムズ株式会社 毛細管、試料採取具、及び試料採取器
US20190086324A1 (en) * 2016-03-23 2019-03-21 Truvian Sciences, Inc. Systems and Methods for Multianalyte Detection

Also Published As

Publication number Publication date
EP3704466A1 (en) 2020-09-09
EP3704466A4 (en) 2021-08-11
EP3704466B1 (en) 2023-10-11
JP7359772B2 (ja) 2023-10-11
WO2019089746A1 (en) 2019-05-09
CN111295577A (zh) 2020-06-16
JP2021503609A (ja) 2021-02-12
US20210086176A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
EP3704466B1 (en) Analyte detection method
Gallart-Ayala et al. A global HILIC-MS approach to measure polar human cerebrospinal fluid metabolome: Exploring gender-associated variation in a cohort of elderly cognitively healthy subjects
Heltsley et al. Oral fluid drug testing of chronic pain patients. II. Comparison of paired oral fluid and urine specimens
Green Indicators for assessing folate and vitamin B12 status and for monitoring the efficacy of intervention strategies
Kapur et al. What the lab can and cannot do: clinical interpretation of drug testing results
Adams et al. Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity
Kameda et al. Reduced uremic metabolites are prominent feature of sarcopenia, distinct from antioxidative markers for frailty
Wang et al. Treatment of rheumatoid arthritis using combination of methotrexate and tripterygium glycosides tablets—a quantitative plasma pharmacochemical and pseudotargeted metabolomic approach
ES2927921T3 (es) Métodos que utilizan paneles de metabolitos para el diagnóstico y diferenciación de la encefalopatía neonatal
WO2018184112A1 (en) Methods of high-throughput mass spectrometry based urine test for colorectal states
Patel et al. Improved detection and precise relative quantification of the urinary cancer metabolite biomarkers–Creatine riboside, creatinine riboside, creatine and creatinine by UPLC-ESI-MS/MS: Application to the NCI-Maryland cohort population controls and lung cancer cases
de Leeuw et al. Quantitation of osimertinib, alectinib and lorlatinib in human cerebrospinal fluid by UPLC-MS/MS
Konieczna et al. Bioanalysis of a panel of neurotransmitters and their metabolites in plasma samples obtained from pediatric patients with neuroblastoma and Wilms' tumor
Rizzo et al. Measurement of succinyl-carnitine and methylmalonyl-carnitine on dried blood spot by liquid chromatography-tandem mass spectrometry
Lehikoinen et al. Alcohol and substance use are associated with altered metabolome in the first trimester serum samples of pregnant mothers
Bai et al. Use of ultra high performance liquid chromatography with high resolution mass spectrometry to analyze urinary metabolome alterations following acute kidney injury in post-cardiac surgery patients
Al-Dirbashi et al. Analysis of methylcitrate in dried blood spots by liquid chromatography-tandem mass spectrometry
Klupczynska-Gabryszak et al. Metabolomics-based search for lung cancer markers among patients with different smoking status
Heales et al. Biogenic amines
Zhang et al. An observation study of urinary biomarker exploratory in Alzheimer's disease using high‐resolution mass spectrometry
Flint et al. Simultaneous quantification of fentanyl, sufentanil, cefazolin, doxapram and keto‐doxapram in plasma using liquid chromatography–tandem mass spectrometry
Janzen et al. UPLC–MS/MS analysis of C5-acylcarnitines in dried blood spots
Kozioł et al. Application of metabolomics in childhood leukemia diagnostics
Jóźwik et al. Current applications of chromatographic methods in the study of human body fluids for diagnosing disorders
de Moraes et al. Combined targeted and untargeted high-resolution mass spectrometry analyses to investigate metabolic alterations in pompe disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231026

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241015

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250903

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102